1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.

2. Marquardt JU, Galle PR, Teufel A. Hepatocellular carcinoma molecular pathogenesis and novel targets for therapy. Dutch Med Wochenschr 2012;137:855-60.

3. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH, Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:111-8.

4. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300-8.

5. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatol J 2003;37:520-7.

6. Choi BG, Park SH, Byun JY, Jung SE, Choi KH, Han JY. The findings of ruptured hepatocellular carcinoma on helical CT. Br J Radiol 2001;74:142-6.

7. Kew MC. Tumors of the liver. In: Zakim D, Boyer T, editors. Hepatology: A textbook of liver disease. 3rd ed. Philadelphia: WB Saunders Company; 1996. p. 1513.

8. Rossetto D, Truman AW, Kron SJ, Côté J. Epigenetic modifications in double-strand break DNA damage signaling and repair. Clin Cancer Res 2010;16:4543-52.

9. Kassianides C, Kew MC. The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol Clin North Am 1987;16:553-62.

10. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43.

11. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.

12. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.

13. Besaratinia A, Kim SI, Hainaut P, Pfeifer GP. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology 2009;137:1127-37.

14. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31.

15. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PH, Lund E, Quirós JR, González CA, Sanchez Perez MJ, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw KT, Wareham N, Key T, Romieu I, Chuang SC, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011;103:1686-95.

16. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004;85:36-41.

17. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;4:14-22.

18. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010;52:252-7.

19. Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep 2011;13:186-94.

20. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008;48:2047-63.

21. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006;66:4766-73.

22. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005;7:26-34.

23. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006;5:4.

24. Das UN, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P. Can tumor cell drug resistance be reversed by essential fatty acids and their metabolites? Prostaglandins Leukot Essent Fatty Acids 1998;58:39-54.

25. Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother 2002;56:215-22.

26. Honarmand H, Mirzajani E, Rahbar-Taromsari M, Saadat F, Mirblock F, Mashayekhi F. The relationship and diagnostic value of C-reactive protein (CRP) and C-reactive protein (hsCRP) for myocardial infarction. Afr J Microbiol Res 2011;5:3215-9.

27. Hutchinson DR, Halliwell RP, Smith MG, Parke DV. Serum "prealbumin" as an index of liver function in human hepatobiliary disease. Clin Chem Acta 1981;114:69-74.

28. Ahmed KM, Saleh EM, Sayed EM, Shalaby KAF. Anti-inflammatory effect ofdifferent propolis extracts in thioacetamide-induced hepatotoxicity in male rat. Aust J Basic App Sci 2012;6:29.

29. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011;9:171.

30. Hassan HA, Edrees GM, El-Gamel EM, El-Sayed EA. Amelioration of cisplatin-induced nephrotoxicity by grape seed proanthocynidin extract and fish oil is mediated by lowering oxidative stress and DNA damage. Cytotechnology 2014;66:419-29.

31. Banakar MC, Paramasivan SK, Chattopadhyay MB, Datta S, Chakraborty P. 1alpha, 25-dihydroxyvitamin D3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J Gastroenterol 2004;10:1268-75.

32. Revathi R, Manju V. The effects of Umbelliferone on lipid peroxidation and antioxidant status in diethylnitrosamine induced hepatocellular carcinoma. Acute J Med 2013;3:73-82.

33. Chen B, Ning M, Yang G. Effect of paeonol on antioxidant and immune regulatory activity in hepatocellular carcinoma rats. Molecules 2012;17:4672-83.

34. Trush MA, Kensler TW. Role of free radicals in carcinogenic activation. In: Sies H, editor. Oxidative Stress: Oxidants and Antioxidants. London, UK: Academic Press; 1991. pp. 277-318.

35. Ljubuncic P, Song H, Cogan U, Azaizeh H, Bomzon A. The effects of aqueous extracts prepared from the leaves of Pastacia lentiscus in experimental liver disease. J Ethnopharmacol 2005;100:198-204.

36. Ahmad A, Pillai KK, Najmi AK, Ahmad SJ, Pal SN, Balani DK. Evaluation of hepatoprotective potential of jigrine post-treatment against thioacetamide induced hepatic damage. J Ethnopharmacol 2002;79:35-41.

37. Chilakapati J, Korrapati MC, Hill RA, Warbritton A, Latendresse JR, Mehendale HM. Toxicokinetics and toxicity of thioacetamide sulfoxide: a metabolite of thioacetamide. Toxicology 2007;230:105-16.

38. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006;12:5113-21.

39. Coward WR, Okayama Y, Sagara H, Wilson SJ, Holgate ST, Church MK. NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J Immunol 2002;169:5287-93.

40. Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. Science 2008;322:1490-4.

41. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003;163:1371-8.

42. Nishikawa H, Kato T, Tawara I, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Old LJ, Shiku H. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 2005;175:4433-40.

43. Huether A, Hopfner M, Sutter AP, Baradari V, Schuppan D, Scherubl H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 2006;12:5160-7.

44. Hu S, Chen SM, Li XK, Qin R, Mei ZN. Antitumor effects of chi-shen extract from Salvia miltiorrhiza and Paeoniae radix on human hepatocellular carcinoma cells. Acta Pharmacol Sin 2007;28:1215-23.

45. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.

46. Paradis V. Histopathology of hepatocellular carcinoma. In: Vauthey JN, Brouquet A, editors. Multidisciplinary treatment of hepatocellular carcinoma. Berlin: Springer; 2013. pp. 21-32.

47. Omata M, Peters RL, Tatter D. Sclerosing hepatic carcinoma: relationship to hypercalcemia. Liver 1981;1:33-49.

48. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Can Chemother Pharmacol 1989;23:S4-8.

49. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012;10:354-62.

50. Kaseb AO, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res 2013;190:247-59.

51. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2012;6:173-85.

52. Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, Aoyagi Y. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med 2013;2:86-98.

53. Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, Lui MC, Yeo W, Chak K, Johnston A, Johnson P. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1999;44:307-11.

54. Leichman CG, Jacobson JR, Modiano M, Daniels JR, Zalupski MM, Doroshow JH, Fletcher WS, Macdonald JS. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: a Southwest Oncology Group pilot trial. Cancer 1999;86:775-81.

55. Hassan HA, El-Gharib NE. Obesity and clinical riskiness relationship: therapeutic management by dietary antioxidant supplementation-a review. Appl Biochem Biotechnol 2015;176:647-69.

56. Kuppusamy P, Yusoff MM, Maniam GP, Ichwan SJ, Soundharrajan I, Govindan N. Nutraceuticals as potential therapeutic agents for colon cancer: a review. Acta Pharm Sinica B 2014;4:173-81.

57. Sousa GT, Lira FS, Rosa JC, de Oliveira EP, Oyama LM, Santos RV, Pimentel GD. Dietary whey protein lessens several risk factors for metabolic diseases: a review. Lipids Health Dis 2012;11:67.

58. Kapadia GJ, Azuine MA, Takayasu J, Konoshima T, Takasaki M, Nishino H, Tokuda H. Inhibition of epstein-barr virus early antigen activation promoted by 12-O-tetradecanoylphorbol-13-acetate by the non-steroidal anti-inflammatory drugs. Cancer Lett 2000;161:221-9.

59. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000;78:199-334.

60. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998;56:317-33.

61. Yamashita H, Goto M, Matsui-Yuasa I, Kojima-Yuasa A. Ecklonia cava polyphenol has a protective effect against ethanol-induced liver injury in a cyclic AMP-dependent manner. Mar Drugs 2015;13:3877-91.

62. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79:727-47.

63. Xiao ZP, Peng ZY, Peng MJ, Yan WB, Ouyang YZ, Zhu HL. Flavonoids health benefits and their molecular mechanism. Mini Rev Med Chem 2011;11:169-77.

64. Donfack JH, Simo CC, Ngameni B, Tchana AN, Kerr PG, Finzi PV, Vidari G, Giardina S, Buonocore D, Ngadjui BT, Moundipa PF, Marzatico F. Antihepatotoxic and antioxidant activities of methanol extract and isolated compounds from Ficus chlamydocarpa. Nat Prod Commun 2010;5:1607-12.

65. Jamshidzadeha A, Khoshnooda JM, Dehghanib Z, Niknaha H. Hepatoprotective activity of Cichorium intybus L. leaves extract against carbon tetrachloride induced toxicity. Iran J Pharm Res 2006;1:41-6.

66. Mulabagal V, Wang H, Ngouajio M, Nair MG. Characterization and quantification of health beneficial anthocyanins in leaf chicory (Cichorium intybus) varieties. Eur Food Res Technol 2009;230:47-53.

67. Nayeemunnisa A. Alloxan diabetes-induced oxidative stress and impairment of oxidative defense system in rat brain: neuroprotective effects of cichorium intybus. Int J Diabetes Metabol 2009;17:105-9.

68. Lee J, Scagel CF. Chicoric acid found in basil (Ocimum basilicum L.) leaves. Food Chem 2009;115:650-6.

69. Dalby-Brown L, Barsett H, Landbo AK, Meyer AS, Mølgaard P. Synergistic antioxidative effects of alkamides, caffeic acid derivatives, and polysaccharide fractions from Echinacea purpurea on. in vitro oxidation of human low-density lipoproteins. Agric J Food Chem 2005;53:9413-23.

70. Hassan HA. The prophylactic role of some edible wild plants against nitrosamine precursor's experimentally-induced testicular toxicity in male albino rats. J Egypt Soc Toxicol 2008;38:1-11.

71. Pool-Zobel B, van Loo J, Rowland I, Roberfroid MB. Experimental evidences on the potential of prebiotic fructans to reduce the risk of colon cancer. Br J Nutr 2002;87:273-81.

72. Cavin C, Delannoy M, Malnoe A, Debefve E, Touché A, Courtois D, Schilter B. Inhibition of the expression and activity of cyclooxygenase-2 by chicory extract. Biochem Biophys Res Commun 2005;327:742-9.

73. Kim JH, Mun YJ, Woo WH, Jeon KS, An NH, Park JS. Effects of the ethanol extract of Cichorium intybus on the immunotoxicity by ethanol in mice. Int Immunopharmacol 2002;2:733-44.

74. Kolida S, Tuohy K, Gibson GR. Prebiotic effect of inulin and oligofructose. Br J Nutr 2002;87:S193-7.

75. Van Beek TA, Maas P, King BM, Leclercq E, Voragen AGJ, De Groot A. Bitter sesquiterpene lactones from chicory roots. Agric J Food Chem 1990;38:1035-8.

76. Kim M, Shin HK. The water-soluble extract of chicory influences serum and liver lipid concentrations, cecal short-chain fatty acid concentrations and fecal lipid excretion in rats. J Nutr 1998;128:1731-6.

77. Roberfroid MB. Inulin-type fructans: functional food ingredients. J Nutr 2007;137:S2493-502.

78. Buriti FCA, Cardarelli HR, Filisetti TMCC, Saad SMI. Synbiotic potential of fresh cream cheese supplemented with inulin and Lactobacillus paracasei in co-culture with Streptococcus thermophilus. Food Chem 2007;104:1605-10.

79. Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applications of silybum marianum in oncology. Integr Cancer Ther 2007;6:158-65.

80. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007;6:110-9.

81. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010;24:1423-32.

82. Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol 2014;92:73-89.

83. Al-Anati L, Essid E, Reinehr R, Petzinger E. Silibinin protects OTA-mediated TNF-alpha release from perfused rat livers and isolated rat Kupffer cells. Mol Nutr Food Res 2009;53:460-6.

84. Fiore C, Eisenhut M, Ragazzi E, Zanchin G, Armanini D. A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol 2005;99:317-24.

85. Orazizadeh M, Fakhredini F, Mansouri E, Khorsandi L. Effect of glycyrrhizic acid on titanium dioxide nanoparticles-induced hepatotoxicity in rats. Chem Biol Interact 2014;220:214-21.

86. Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 2008;22:709-24.

87. Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol 2012;18:679-84.

88. Furuta K, Sato S, Miyake T, Okamoto E, Ishine J, Ishihara S, Amano Y, Adachi K, Kinoshita Y. Anti-tumor effects of cimetidine on hepatocellular carcinomas in diethylnitrosamine-treated rats. Oncol Rep 2008;19:361-8.

89. El Denshary ES, Al-Gahazali MA, Mannaa FA, Salem HA, Hassan NS, Abdel-Wahhab MA. Dietary honey and ginseng protect against carbon tetrachloride-induced hepatonephrotoxicity in rats. Exp Toxicol Pathol 2012;64:753-60.

90. Soldati F. Panax ginseng: standardization and biological activity In: Cutler SJ, Cutler HG, editors. Biologically active natural products: pharmaceuticals. Boca Raton, FI: CRC Press; 2000. pp. 209-32.

91. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004;27:1-19.

92. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, Kobayashi K, Tango T. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743-9.

93. Abdel-Wahhab MA, Gamil K, El-Kady AA, El-Nekeety AA, Naguib KM. Therapeutic effects of korean red ginseng extract in egyptian patients with chronic liver diseases. Ginseng J Res 2011;35:69-79.

94. He SX, Luo JY, Wang YP, Wang YL, Fu H, Xu JL, Zhao G, Liu EQ. Effects of extract from Ginkgo biloba on carbon tetrachloride-induced liver injury in rats. World J Gastroenterol 2006;12:3924-8.

95. Nishino H, Tokuda H, Ii T, Takemura M, Kuchide M, Kanazawa M, Mou XY, Bu P, Takayasu J, Onozuka M, Masuda M, Satomi Y, Konoshima T, Kishi N, Baba M, Okada Y, Okuyama T. Cancer chemoprevention by ginseng in mouse liver and other organs. J Korean Med Sci 2001;16:S66-9.

96. Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev 1995;4:401-8.

97. Hasegawa H, Sung JH, Matsumiya S, Uchiyama M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 1996;62:453-7.

98. Lee BM, Lee SK, Kim HS. Inhibition of oxidative DNA damage, 8-OHdG, and carbonyl contents in smokers treated with antioxidants (vitamin E, vitamin C, beta-carotene and red ginseng). Cancer Lett 1998;132:219-27.

99. Choi HH, Jong HS, Park JH, Choi S, Lee JW, Kim TY, Otsuki T, Namba M, Bang YJ. A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells. Int J Oncol 2003;23:1087-93.

100. Choi UK, Lee OH, Yim JH, Cho CW, Rhee YK, Lim SI, Kim YC. Hypolipidemic and antioxidant effects of dandelion (taraxacum officinale) root and leaf on cholesterol-fed rabbits. Int J Mol Sci 2010;11:67-78.

101. Schütz K, Carle R, Schieber A. Taraxacum--a review on its phytochemical and pharmacological profile. J Ethnopharmacol 2006;107:313-23.

102. Wichtl M. Herbal drugs and phytopharmaceuticals. A handbook for practice on a scientific basis. 3rd ed. Boca Raton, FI: CRC Press; 2004. p. 704.

103. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press; 1996. p. 296.

104. Jeon HJ, Kang HJ, Jung HJ, Kang YS, Lim CJ, Kim YM, Park EH. Anti-inflammatory activity of Taraxacum officinale. J Ethnopharmacol 2008;115:82-8.

105. Williams CA, Goldstone F, Greenham J. Flavonoids, cinnamic acids and coumarins from the different tissues and medicinal preparations of Taraxacum officinale. Phytochemistry 1996;42:121-7.

106. Hu C, Kitts DD. Antioxidant, prooxidant, and cytotoxic activities of solvent-fractionated dandelion (Taraxacum officinale) flower extracts in vitro. J Agric Food Chem 2003;1:301-10.

107. Al-Malki AL, Abo-Golayel MK, Abo-Elnaga G, Al-Beshri H. Hepatoprotective effect of dandelion (Taraxacum officinale) against induced chronic liver cirrhosis. Med Plants Res 2013;7:1494-505.

108. Park JY, Park CM, Kim JJ, Song YS. Hepatoprotective activity of dandelion (Taraxacum officinale) water extract against Dgalactosamine-induced hepatitis in rats. Korean J Soc Food Sci Nut 2008;32:177-83.

109. Hudec J, Burdová M, Kobida L, Komora L, Macho V, Kogan G, Turianica I, Kochanova R, Ložek O, Habán M, Chlebo P. Antioxidant capacity changes and phenolic profile of Echinacea purpea, nettle (Urtica dioica L.), and dandelion (Taraxacum officinale) after application of polyamine and phenolic biosynthesis regulators. Agric J Food Chem 2007;55:5689-96.

110. Seo SW, Koo HN, An HJ, Kwon KB, Lim BC, Seo EA, Ryu DG, Moon G, Kim HY, Kim HM, Hong SH. Taraxacum officinale protects against cholecystokinin-induced acute pancreatitis in rats. World J Gastroenterol 2005;11:597-9.

111. Rana SV, Pal R, Vaiphei K, Sharma SK, Ola RP. Garlic in health and disease. Nutr Res Rev 2011;24:60-71.

112. Herman-Antosiewicz A, Singh SV. Signal transduction pathways leading to cell cycle arrest and apoptosis induction in cancer cells by Allium vegetable-derived organosulfur compounds: a review. Mutat Res 2004;555:121-31.

113. Chu Q, Lee DT, Tsao SW, Wang X, Wong YC. S-allylcysteine, a water-soluble garlic derivative, suppresses the growth of a human androgen-independent prostate cancer xenograft, CWR22R, under in vivo conditions. BJU Int 2007;99:925-32.

114. Gapter LA, Yuin OZ, Ng KY. S-Allylcysteine reduces breast tumor cell adhesion and invasion. Biochem Biophys Res Commun 2008;367:446-51.

115. Tang FY, Chiang EP, Chung JG, Lee HZ, Hsu CY. S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. J Nutr Biochem 2009;20:1013-20.

116. Welch C, Wuarin L, Sidell N. Antiproliferative effect of the garlic compound S-allyl cysteine on human neuroblastoma cells in vitro. Cancer Lett 1992;63:211-9.

117. Tang FY, Chiang EP, Pai MH. Consumption of S-allylcysteine inhibits the growth of human non-small-cell lung carcinoma in a mouse xenograft model. J Agric Food Chem 2010;58:11156-64.

118. Chu YL, Ho CT, Chung JG, Raghu R, Lo YC, Sheen LY. Allicin induces anti-human liver cancer cells through the p53 gene modulating apoptosis and autophagy. J Agric Food Chem 2013;61:9839-48.

119. Bryja V, Gradl D, Schambony A, Arenas E, Schulte G. Beta-arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci U S A 2007;104:6690-5.

120. Zhang CL, Zeng T, Zhao XL, Yu LH, Zhu ZP, Xie KQ. Protective effects of garlic oil on hepatocarcinoma induced by N-nitrosodiethylamine in rats. Int J Biol Sci 2012;8:363-74.

121. Sundaresan S, Subramanian P. Prevention of N-nitrosodiethylamine-induced hepatocarcinogenesis by S-allylcysteine. Mol Cell Biochem 2008;310:209-14.

122. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: a review. Curr Pharm Biotechnol 2012;13:218-28.

123. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of curcima longa: a review of preclinical and clinical research. Altern Med Rev 2009;14:141-53.

124. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75.

125. Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappa B, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta 2007;1770:989-96.

126. Hsu FT, Liu YC, Liu TT, Hwang JJ. Curcumin sensitizes hepatocellular carcinoma cells to radiation via suppression of radiation-induced NF-κB activity. Biomed Res Int 2015;2015:363671.

127. Soliman MM, Baiomy AA, Yassin MH. Molecular and histopathological study on the ameliorative effects of curcumin against lead acetate-induced hepatotoxicity and nephrotoxicity in Wistar rats. Biol Trace Elem Res 2015;167:91-102.

128. Skommer J, Wlodkowic D, Pelkonen J. Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp Hematol 2007;35:84-95.

129. Dai XZ, Yin HT, Sun LF, Hu X, Zhou C, Zhou Y, Zhang W, Huang XE, Li XC. Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev 2013;14:3855-9.

130. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98.

131. Hamzawy MA, El-Denshary ES, Hassan NS, Manaa F, Abdel-Wahhab MA. Antioxidant and hepatorenoprotective effects of Thyme vulgaris extract in rats during aflatoxicosis. Glob J Pharmacol 2012;6:106-17.

132. Hamzawy MA, El-Denshary ESM, Abdel-Wahhab MA. Effects of natural compounds in treatment and prevention of hepatotoxicity and hepatocellular carcinoma. Hepatoma Res 2015;1:111-8.

133. Hosseinzadeh S, Kukhdan AJ, Hosseini A, Armand R. The application of Thymus vulgaris in traditional and modern medicine: a review. Global J Pharmacol 2015;9:260-6.

134. Marculescu A, Vlase L, Hanganu D, Dragulescu C, Antonie I, Neli-Kinga O. Polyphenols analyses from Thymus species. Proc Rom Acad Series B 2007;3:117-21.

135. Thompson JD, Chalchat JC, Michet A, Linhart YB, Ehlers B. Qualitative and quantitative variation in monoterpene co-occurrence and composition in the essential oil of Thymus vulgaris chemotypes. J Chem Ecol 2003;29:859-80.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: